EF
NVCR icon

Empowered Funds’s NovoCure NVCR Stock Holding History

Empowered Funds’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,741
Closed -$1.48M – 278
2021
Q3 		$1.48M Buy
12,741
+3,237
+34% +$489K 0.19% 128
2021
Q2 		$2.11M Buy
+9,504
New +$1.85M 0.27% 96
2020
Q2 		– Sell
-13,840
Closed -$1.17M – 139
2020
Q1 		$1.17M Hold
13,840
– – 0.42% 96
2019
Q4 		$1.17M Buy
13,840
+707
+5% +$57.1K 0.42% 96
2019
Q3 		$982K Sell
13,133
-7,803
-37% -$624K 0.43% 86
2019
Q2 		$1.32M Sell
20,936
-6,455
-24% -$327K 0.55% 51
2019
Q1 		$1.32M Buy
+27,391
New +$1.32M 0.47% 90

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Empowered Funds's NVCR Position: Q4 2021 in Review

Empowered Funds sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 12,741 shares — an estimated $1.48M sold.

Empowered Funds first reported a position in NVCR in Q1 2019 and held it in 7 quarters. The position peaked at $2.11M in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Empowered Funds reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Empowered Funds sold 12,741 NovoCure shares in Q4 2021, an estimated $1.48M.
  • Empowered Funds first reported a position in NovoCure in Q1 2019 and held it in 7 quarters.
  • Empowered Funds's NovoCure position peaked at $2.11M in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Empowered Funds's 13F filing for Q4 2021, filed 10 Feb 2022.